Atezolizumab (Tecentriq)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses atezolizumab for injection (Tecentriq), solution for IV infusion, 1,200 mg/20 mL.
• Indication: In combination with carboplatin and etoposide for the first-line treatment of adult patients with extensive-stage small cell lung cancer.